
Hikma successfully completes \$500 million 5-year Eurobond issue

London, July 9, 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company rated BBB- / stable (S&P) and Ba1 / stable (Moody's), announces that it has successfully completed a \$500 million 5-year Eurobond, which will carry an annual coupon of 3.25%.

Khalid Nabilsji, Hikma CFO said, "We are very pleased to announce the successful placement of this Eurobond despite the COVID-19 pandemic which has caused uncertainty in the financial markets. The bond was three times oversubscribed backed by high interest from investors globally – a clear indication of the continuing confidence of international investors in our financial prospects. The net proceeds of the issue will strengthen the company's financial position and provide the financial flexibility to capitalize on opportunities to support our strategic growth plans."

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BBB-/stable S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2020 Hikma Pharmaceuticals PLC. All rights reserved.